<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845959</url>
  </required_header>
  <id_info>
    <org_study_id>TD0019.02</org_study_id>
    <nct_id>NCT03845959</nct_id>
  </id_info>
  <brief_title>A Trial of TD0019 in Treatment of Cervical Scapulohumeral Syndrome</brief_title>
  <official_title>NGHIÊN CỨU NGẪU NHIÊN, MÙ ĐÔI, CÓ ĐỐI CHỨNG TRONG ĐIỀU TRỊ HỘI CHỨNG CỔ VAI CÁNH TAY CỦA VIÊN NANG CỨNG TD 0019 (A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Satety and Efficacy of Therapy With Hard Capsule TD0019 in Cervical Scapulohumeral Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunstar Joint Stock Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Big Leap Clinical Research Joint Stock Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunstar Joint Stock Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical scapulohumeral syndrome, which is also called scapulohumeral syndrome or cervical
      radiculopathy is a group of syndromes related to cervical spine disorders with disfunctional
      nerves and without inflamation. The physical syndromes vary from neck pain, Sensory
      Processing Disorder/Movenment Disorder of areas dominated by injured nerves.

      The hard capsule TD0019 is a product based on the traditional prescription named &quot;Độc hoạt
      tang ký sinh thang&quot; combined with Nattokinase and the extraction of Salix alba Cortex

      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical scapulohumeral syndrome, which is also called scapulohumeral syndrome or cervical
      radiculopathy is a group of syndromes related to cervical spine disorders with disfunctional
      nerves and without inflamation. The physical syndromes vary from neck pain, hands,
      accompanied by a Sensory Processing Disorder/Movenment Disorder of areas dominated by injured
      nerves. The most common reason is Cervical spondylosis The hard capsule TD0019 is a product
      based on the traditional prescription named &quot;Độc hoạt tang ký sinh thang&quot; combined with
      Nattokinase and the extraction of Salix alba Cortex.

      The trial lasts for 24 months with 4 subject visits (from T0 to T3) and is conducted in
      National Hospital of Traditional Medicine (Hanoi, Vietnam).

      Screening procedure occurs at T0 visit, followed by T1 (15+-3 days) and T2 (30+-3 days).

      There are 2 levels of dosages: basic dose (arm 1) and 1.5x (arm 2) of basic dose.

      There is also another arm using placebo, thus the trial have 3 arms in total.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three arms: basic dose, 1.5 basic dose and placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Pain Scores on the Visual Analog Scale at day 15th, day 30th, 1 month after end of study.</measure>
    <time_frame>day 15th, day 30th, 1 month after end of study.</time_frame>
    <description>VAS scale: 0 = no pain | 0--&gt;2: mild | 2--&gt;4: moderate | 4--&gt; 6: severe | 6-&gt;8: extreme | 8--&gt;10: untolerable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Range of Motion of cervical spine</measure>
    <time_frame>day 15th, day 30th, 1 month after end of study.</time_frame>
    <description>Analog and traditional devices to measure range of motion in the joints of the body include the goniometer and inclinometer which use a stationary arm, protractor, fulcrum, and movement arm to measure angle from axis of the joint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptoms of nerve root compression</measure>
    <time_frame>day 15th, day 30th, 1 month after end of study.</time_frame>
    <description>The presence of numbness or weakness of the buttock and leg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in limitation of daily rountines</measure>
    <time_frame>day 15th, day 30th, 1 month after end of study.</time_frame>
    <description>Neck Disability Index at day 15th, day 30th, 1 month after end of study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of AE, SAE.</measure>
    <time_frame>1 month</time_frame>
    <description>CTCAE 4.0</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Syndrome Pain</condition>
  <arm_group>
    <arm_group_label>TD0019.6cap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>estimated dose, 2 oral capsules/time x 3 times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD0019.9cap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 times of estimated dose 2 oral capsules/time x 3 times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 placebo oral capsules /time x 3 times/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD0019 oral capsule</intervention_name>
    <description>TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.</description>
    <arm_group_label>TD0019.6cap</arm_group_label>
    <arm_group_label>TD0019.9cap</arm_group_label>
    <other_name>Vien Vai Gay Thai Duong</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject must meet all below criteria to be enrolled:

          -  Subjects diagnosed with cervical scapulohumeral syndrome according to the Guideline of
             Vietnam MOH 2014

          -  Age &gt; 18 at time of signing ICF, male or female.

          -  No contraindications with oral NSAIDs.

          -  Agree and and sign in the ICF

        Exclusion Criteria:

        Subjects will be excluded in the trial if any of the below are met:

          -  Hypersensitivity to any subtances of TD0019 or any NSAIDs.

          -  Pregnant or lactating.

          -  Currently having surgical indications.

          -  Movement disorders, diabetes, myasthenia, alcoholism

          -  Other conditions asseted by the investigator that are not eligible to be enrolled.

          -  Cervical scapulohumeral syndrome caused by tumor, infection, hypertension, physical
             injured.

          -  Arrhythmia, hypertension.

          -  Hypertensitivity to meloxicam or its excipients.

          -  Cross - hypertensitivity to aspirin or other NSAIDs.

          -  Peptic ulcer

          -  Severe liver failure

          -  Severe renal failure without dialysis.

          -  Gastrointestinal hemorrhage, recent brain hemorrhage.

          -  Uncontrolled heart failure.

          -  Alcoholism, movement disorders, diabetes, muscular dystrophy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Hospital of Traditional Medicine</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>February 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>February 16, 2019</last_update_submitted>
  <last_update_submitted_qc>February 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

